Evidence of proteolytic activation of transforming growth factor beta in synovial fluid.
Zielinski
S
S
Clinic of Rheumatology, Otto-von-Guericke-University of Magdeburg, Germany.
Bartels
K
K
Cebulski
K
K
Kühne
C
C
Kekow
J
J
D007611:Aprotinin / Q000494:pharmacology; D001168:Arthritis / Q000201:enzymology; D004789:Enzyme Activation; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D019278:Matrix Metalloproteinase 3 / Q000302:isolation & purification / Q000502:physiology; D061965:Matrix Metalloproteinase Inhibitors; D010618:Phenanthrolines / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000302:isolation & purification / Q000502:physiology*; D013582:Synovial Fluid / Q000201:enzymology*; D016212:Transforming Growth Factor beta / Q000009:adverse effects / Q000302:isolation & purification / Q000502:physiology*; D053781:Transforming Growth Factor beta2
D061965:Matrix Metalloproteinase Inhibitors; D010618:Phenanthrolines; D011480:Protease Inhibitors; D020033:Protein Isoforms; C509041:TGFB2 protein, human; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2; D007611:Aprotinin; D019278:Matrix Metalloproteinase 3; D007930:Leucine; C024974:E 64; C025205:1,10-phenanthroline